VCRC Tissue Repository
NCT02967068 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 1000
Last updated 2026-01-22
Summary
The purpose of this study is to collect existing tissue specimens from subjects enrolled in Vasculitis Clinical Research Consortium (VCRC) studies. Analysis of these tissue specimens and linked clinical data collected through VCRC studies may lead to the identification and development of a series of translational research projects. Results of these studies will provide vasculitis researchers with insight into the causes of these diseases and generate new ideas for diagnostic tests and therapies, and will be of great interest to the larger communities of researchers investigating vasculitis and other autoimmune, inflammatory, and vascular diseases.
Conditions
- Aortitis
- Cutaneous Vasculitis
- Eosinophilic Granulomatosis With Polyangiitis
- Giant Cell Arteritis
- Granulomatosis With Polyangiitis (Wegener's)
- Henoch-Schonlein Purpura
- IgA Vasculitis
- Microscopic Polyangiitis
- Polyarteritis Nodosa
- Takayasu Arteritis
- Churg-Strauss Syndrome
Sponsors & Collaborators
-
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
collaborator NIH -
National Center for Advancing Translational Sciences (NCATS)
collaborator NIH -
Office of Rare Diseases (ORD)
collaborator NIH - lead OTHER
Principal Investigators
-
Peter A Merkel, MD, MPH · University of Pennsylvania
Eligibility
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2016-11-30
- Primary Completion
- 2028-12-31
- Completion
- 2028-12-31
Countries
- United States
- Canada
Study Locations
More Related Trials
-
Educational Needs of Patients With Systemic Vasculitis
NCT02190929 ·Status: COMPLETED
-
Longitudinal Protocol for Granulomatosis With Polyangiitis (Wegener's) and Microscopic Polyangiitis
NCT00315393 ·Status: COMPLETED
-
Analysis of Bronchial Tissue and Fluid in Patients With Wegener's Granulomatosis
NCT00001541 ·Status: COMPLETED
-
Biocollection of Patients With ANCA Associated Vasculitis
NCT05364892 ·Status: RECRUITING ·Phase: NA
-
Reproductive Health in Men and Women With Vasculitis
NCT02176070 ·Status: COMPLETED
-
Clinical Transcriptomics in Systemic Vasculitis (CUTIS)
NCT03004326 ·Status: RECRUITING
-
Vasculitis Illness Perception (VIP) Study
NCT02190916 ·Status: COMPLETED
-
Determining Disease Activity Biomarkers in Individuals With Giant Cell Arteritis
NCT00315497 ·Status: COMPLETED
-
Vasculitis Pregnancy Registry
NCT02593565 ·Status: RECRUITING
-
The ANCA Vasculitis Questionnaire (AAV-PRO©)
NCT02507024 ·Status: COMPLETED
-
Biologics in Refractory Vasculitis: A Trial of Biologic Therapy for Refractory Primary Non-ANCA Associated Vasculitis
NCT05168475 ·Status: TERMINATED ·Phase: PHASE2
-
Hematopoietic Stem Cell Support in Vasculitis
NCT00278512 ·Status: TERMINATED ·Phase: PHASE1
-
Neutrophils as Prognostic Factors in Granulomatosis With Polyangiitis (Formerly Named Wegener's Granulomatosis)
NCT01862068 ·Status: COMPLETED
-
Aetiology of TemporaL Arteritis Study
NCT02584517 ·Status: WITHDRAWN
-
Rituximab for the Treatment of Wegener's Granulomatosis and Microscopic Polyangiitis
NCT00104299 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Intravenous Immunoglobulin After Relapse in Vasculitis
NCT00307658 ·Status: TERMINATED ·Phase: PHASE3
-
PRO Development for ANCA Associated Vasculitis
NCT01729624 ·Status: UNKNOWN
-
Defining Immune Tolerance in ANCA-associated Vasculitis (AAV)
NCT01934504 ·Status: TERMINATED
-
A Study to Evaluate the Safety and Efficacy of CCX168 in Subjects With ANCA-Associated Vasculitis
NCT01363388 ·Status: COMPLETED ·Phase: PHASE2
-
A Phase 3 Clinical Trial of CCX168 (Avacopan) in Patients With ANCA-Associated Vasculitis
NCT02994927 ·Status: COMPLETED ·Phase: PHASE3
-
Belimumab in Remission of VASculitis
NCT01663623 ·Status: COMPLETED ·Phase: PHASE3
-
Tailoring Maintenance Therapy to Cluster of Differentiation 5 Positive (CD5+) Regulatory B Cell Recovery in ANCA Vasculitis
NCT03906227 ·Status: TERMINATED ·Phase: NA
-
Study of Eye Tissue for Sarcoidosis
NCT00001278 ·Status: COMPLETED
-
PR3-AAV Resilient Remission or PRRR
NCT05376319 ·Status: TERMINATED ·Phase: PHASE2
-
Alemtuzumab for ANCA Associated Refractory Vasculitis
NCT01405807 ·Status: UNKNOWN ·Phase: PHASE4